Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease

Wiener Klinische Wochenschrift

Volumn 126, Issue 15-16, 2014, Pages 474-479

  Mikolasevic, Ivana ^a   Orlic, Lidija ^a   Milic, Sandra ^a   Lukenda, Vesna ^b   Racki, Sanjin ^a   Stimac, Davor ^a   Avdovic, Ervin ^a   Zaputovic, Luka ^a  

^a KBC RIJEKA   (Croatia)

^b DR JOSIP BEN EVI GENERAL HOSPITAL   (Croatia)

Author keywords

Coronary heart disease; Nonalcoholic fatty liver disease (NAFLD); Transient elastography

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; ELASTOGRAPH; ELASTOGRAPHY; FATTY LIVER; FEMALE; HEART CATHETERIZATION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; RIGIDITY; TRANSIENT ELASTOGRAPHY; COMPLICATION; CORONARY ARTERY DISEASE; ECHOGRAPHY; LIVER CIRRHOSIS; MIDDLE AGED; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

CORONARY ARTERY DISEASE; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84906940111     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-014-0538-0     Document Type: Article

References (24)

1. Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis. 2012;30:158-62.
2. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008;51:1947-53.
3. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473-80. (Pubitemid 41061101)
4. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-40.
5. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235-40. (Pubitemid 46400718)
6. Kim CH, Younossi ZM. Non alcoholic fatty liver disease: a manifestation of metabolic syndrome. Cleve Clin J Med. 2008;75:721-8.
7. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med. 2007;24:1-6. (Pubitemid 46103064)
8. Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325-35.
9. Chowdhury SD, Ramakrishna B, Eapen CE, Goel A, Zachariah UG, Chandramohan A, et al. Fibrosis in non-alcoholic fatty liver disease: correlation with simple blood indices and association with tumor necrosis factor-alpha polymorphisms. Trop Gastroenterol. 2013;34:31-5.
10. Celikbilek M, Dogan S, Gursoy S, Zararsiz G, Yurci A, Ozbakir O, et al. Noninvasive assessment of liver damage in chronic hepatitis B. World J Hepatol. 2013;5:439-45.
11. Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:775-82. (Pubitemid 46529041)
12. Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:782-9.
13. Sasso M, Beaugrand M, dee Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825-35.
14. Wong Lai-Hung G. Update of liver fibrosis and steatosis with transiet elastography (Fibroscan®). Gastroenterol Rep. 2013:1-8. doi:10.1093/gastro/ got007.
15. Grundy SM, Cleeman JI, Daniels SR, et al American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735-52. (Pubitemid 41532612)
16. Inci MF, Özkan F, Ark B, et al. Sonographic evaluation for predicting the presence and severity of coronary artery disease. Ultrasound Q. 2013;29:125-30.
17. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5:1544-60.
18. Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists. J Obes. 2012;2012:483135.
19. Schindhelm RK, Diamant M, Bakker SJ, et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest. 2005;35:369-74. (Pubitemid 40826835)
20. Goland S, Shimoni S, Zornitzki T, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol. 2006;40:949-55. (Pubitemid 44690772)
21. Targher G, Bertolini L, Padovani R, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29:1325-30. (Pubitemid 44125930)
22. Fracanzani AL, Burdick L, Raselli S, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med. 2008;121:72-8.
23. Cervera-Lizardi J, Zapata-Aguilar D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol. 2009;8:40-3.
24. Schwimmer JB, Deutsch R, Behling C, et al. Fatty liver as a determinant of atherosclerosis. Hepatology. 2005;42:610A (abstract).